Prenatal Testing & Newborn Screening Market Report 2026

The prenatal testing & newborn screening market size has grown rapidly in recent years. It will grow from $6.98 billion in 2025 to $7.84 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to expansion of public health screening initiatives, increasing institutional births, availability of neonatal care facilities, rising focus on early disease detection, improvements in diagnostic testing coverage.

The prenatal testing & newborn screening market size is expected to see rapid growth in the next few years. It will grow to $12.22 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing expansion of national screening mandates, rising adoption of digital diagnostic platforms, growing investments in maternal and child healthcare, increasing focus on preventive healthcare models, expanding use of ai-assisted diagnostics. Major trends in the forecast period include increasing adoption of integrated prenatal and newborn screening programs, rising use of combined screening and diagnostic technologies, growing implementation of early intervention protocols, expansion of automated screening workflows, enhanced focus on population-wide screening.

The high prevalence of genetic diseases in infants has contributed to the growth of the prenatal testing and newborn screening market. Genetic diseases include conditions such as thalassemia, sickle cell anemia, hemophilia, cystic fibrosis, Tay Sachs disease, fragile X syndrome, and Huntington’s disease. Sickle cell anemia is among the most widespread genetic disorders globally and is particularly prevalent among populations with ancestry from Africa, the Americas, Cuba, Central America, Saudi Arabia, and India. For instance, in February 2023, according to the Rady Children’s Institute for Genomic Medicine, a US-based research institute, a study conducted at Rady Children’s Hospital found that 41% of infant deaths were attributed to single-locus, or Mendelian, genetic diseases. The high prevalence of genetic diseases in infants has therefore increased demand and driven the growth of the prenatal testing and newborn screening market.

The increase in the birth rate is expected to propel the growth of the prenatal testing and newborn screening market going forward. The birth rate, also referred to as natality, is defined as the total number of live births per 1,000 people within a population over a specific time period. Prenatal testing supports the evaluation of fetal health before birth, while newborn screening helps identify certain medical conditions shortly after delivery, enabling early diagnosis and timely intervention. For instance, in April 2024, according to a report published by the Centers for Disease Control and Prevention, a US-based government agency, the cesarean delivery rate increased for the fourth consecutive year in 2023, reaching 32.4%, while the rate of low-risk cesarean deliveries rose to 26.6%. Therefore, the rising birth rate is supporting the growth of the prenatal testing and newborn screening market.

Major companies operating in the prenatal testing and newborn screening market are focusing on the development of innovative newborn screening devices to improve early detection of genetic, metabolic, and other health conditions, enabling timely interventions and better health outcomes for newborns. Newborn screening point-of-care devices are designed to deliver faster, more accessible, and cost-effective screening solutions and can accommodate the standard newborn screening tests conducted globally. For instance, in September 2023, Mylab Discovery Solutions Pvt. Ltd., an India-based company, launched MyNeoShield, a newborn screening point-of-care device. MyNeoShield is designed to be low cost, estimated at about one-fifth the price of existing solutions, which often range from ₹50 lakhs to ₹7 crores. By bringing testing directly to healthcare providers, MyNeoShield aims to expand access to essential newborn health services, particularly in underserved regions.

Major companies operating in the prenatal testing & newborn screening market are PerkinElmer Inc, Laboratory Corporation Of America Holdings, Natera Inc, Invitae Corporation, Centogene AG, Cradle Genomics Inc, Roche Diagnostics International AG, Quest Diagnostics Incorporated, Baebies Inc, Progenity Inc, Ravgen Inc, Strand Life Sciences Pvt Ltd, Eurofins Scientific, Illumina Inc, Agilent Technologies Inc, Thermo Fisher Scientific Inc, F Hoffmann La Roche Ltd, Bio Rad Laboratories Inc, Siemens Healthineers AG, BGI Group, QIAGEN NV, Ariosa Diagnostics Inc, Verinata Health Inc, Counsyl A Myriad Company, GenPath Diagnostics, Sonic Healthcare Limited, Cepheid A Danaher Company.

North America was the largest region in the prenatal testing & newborn screening market in 2025. Western Europe was the second largest region in the prenatal testing and newborn screening market. The regions covered in the prenatal testing & newborn screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prenatal testing & newborn screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the prenatal testing and newborn screening market by increasing costs of imported diagnostic instruments, assay kits, automation systems, and laboratory consumables used in screening and confirmation testing. Public healthcare systems and diagnostic centers in North America and Europe are most impacted due to reliance on imported technologies, while Asia-Pacific faces cost pressures on expanding screening infrastructure. These tariffs are increasing operational costs and slowing program scale-up. However, they are also encouraging domestic manufacturing of screening kits, regional laboratory automation development, and localized supply chain investments.

The prenatal testing & newborn screening market research report is one of a series of new reports that provides prenatal testing & newborn screening market statistics, including prenatal testing & newborn screening industry global market size, regional shares, competitors with a prenatal testing & newborn screening market share, detailed prenatal testing & newborn screening market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal testing & newborn screening industry. This prenatal testing & newborn screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prenatal testing and newborn screening encompass medical practices designed to evaluate the health of the fetus during pregnancy and the newborn after birth. Prenatal testing includes assessments such as blood tests and ultrasounds that help identify potential genetic or developmental abnormalities in the fetus. Newborn screening consists of tests performed shortly after birth to detect metabolic, genetic, and endocrine disorders, enabling early diagnosis and timely treatment to improve infant health outcomes.

The primary diagnostic approaches used in prenatal testing and newborn screening are non-invasive and invasive methods. Invasive diagnostic testing involves penetrating the skin or entering the body and includes procedures such as blood tests, biopsies, and colonoscopies. The technologies used include screening technologies and diagnostic technologies, which are applied across healthcare settings such as hospitals and diagnostic centers.

The prenatal testing & newborn screening market includes revenues earned by entities by providing blood test services, hearing test services, CCHD screening tests, and non-invasive tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.